PRPO - Precipio, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
+0.0005 (+0.24%)
At close: 3:58PM EST

0.2150 +0.01 (4.57%)
After hours: 5:51PM EST

Stock chart is not supported by your current browser
Previous Close0.2051
Bid0.2056 x 1000
Ask0.2150 x 3000
Day's Range0.2040 - 0.2150
52 Week Range0.1500 - 1.7500
Avg. Volume1,602,488
Market Cap6.247M
Beta (3Y Monthly)2.95
PE Ratio (TTM)N/A
EPS (TTM)-1.5840
Earnings DateNov 19, 2018 - Nov 20, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Makati Medical Center in the Philippines Adopts Precipio’s ICE COLD-PCR Mutation Enrichment Technology for Liquid Biopsies

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that Makati Medical Center (MakatiMed) in Manila, the Philippines, has placed its first order for ICE COLD-PCR (ICP) as part of its agreement to serve as the exclusive central laboratory in the Philippines for Precipio’s ICP liquid biopsy technology.

  • ACCESSWIRE3 days ago

    Best Bounces to Play the Rally

    HENDERSON, NV / ACCESSWIRE / January 14, 2019 / With the market rallying this week, several oversold stocks are starting to make solid gains. We've found a few stocks that look set up to continue this ...

  • GlobeNewswire7 days ago

    Precipio Announces First US Government Customer for ICE COLD-PCR™ Mutation Enrichment Technology

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has been approved by the United States Department of Defense (DoD) as a domestic vendor within the Foundation for the Advancement of military medicine. Approval as a vendor will enable DoD funded medical centers to utilize Precipio ICE COLD-PCR (ICP) technology in mutation testing for both active duty as well as military veterans. A hospital within the DoD evaluated several technologies including the competing Droplet Digital PCR (ddPCR), and ultimately decided that Precipio’s ICE-COLD PCR (ICP) enrichment technology for liquid biopsies was to be used at its facility.

  • GlobeNewswire9 days ago

     Precipio Files Patent for HemeScreen™, its Novel Molecular Assay

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the filing of a patent for its proprietary HemeScreen panel. The panel incorporates a novel method for analyzing four key genes typically evaluated for mutations in patients with hematologic malignancies. In 2016, The World Health Organization (WHO) published guidelines recommending the testing of the JAK2 (V617F mutation), JAK2 Exon 12, MPL and CALR genes as part of the evaluation for patients suspected to have Myelodysplastic Syndrome (MDS) and Myeloproliferative Disorders (MPD), two of the most common hematologic (blood-related) cancers.

  • GlobeNewswirelast month

    Precipio Reports Strong Mid-Quarter Growth

    Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that based on metrics observed in its October and November revenue numbers (quarter-to-date), the company is on track for continued strong Quarter-over-Quarter revenue growth. Preliminary (unaudited) pathology services revenues in November increased 16% from October, keeping in line with expected Q4 total quarterly revenue growth in excess of 25% over Q3, driven by strong growth in both clinical revenue and pharma services. Additionally, the number of ordering physicians increased by a healthy 30% for the same period, and case volume increased, indicating strong adoption of the company’s offering and a promising pipeline of future revenue growth.

  • GlobeNewswirelast month

    Precipio Announces $1.2 Million Securities Purchase Agreement With Participation from Members of Its Board of Directors, and other Investors

    Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has entered into a $1.2 million Securities Purchase Agreement with several existing investors, as well as two members of its Board of Directors. “We are encouraged by the endorsement of our investors, and in particular the support of two members of our Board of Directors, who have again demonstrated their support of the company as we continue to grow the business, and refine our suite of products and services for the cancer diagnostics market,” said Ilan Danieli, CEO of Precipio. On November 29, 2018, the Company entered into an agreement which provides for the issuance of up to $1.2M in additional notes, together with applicable warrants.

  • ACCESSWIRE2 months ago

    The Reason Healthcare Stocks Are Being Called Home By Investors

    CORAL GABLES, FL / ACCESSWIRE / November 27, 2018 / Healthcare stocks helped boost the stock market rally on Monday. Recently concluded mid-term elections have provided a much-needed boost to the healthcare sector. New trends that the majority of healthcare companies are working on are also boosting the sector.

  • GlobeNewswire2 months ago

    Precipio ICE COLD-PCR™ Technology Selected by the University of Cincinnati Medical Center for Liquid Biopsy Study

    Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that its ICE COLD-PCR™ (ICP) technology has been selected for a screening study to identify clinically actionable mutations in non-small cell lung cancer (NSCLC) at the University of Cincinnati Medical Center. The study will focus on utilizing ICP mutation enrichment along with High Resolution Melt Analysis (HRM) screening technology to screen actionable mutations in epidermal growth factor receptor (EGFR) for NSCLC.

  • GlobeNewswire2 months ago

    Letter to Shareholders to accompany recent proxy filing

    Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), yesterday filed a proxy statement in advance of a special shareholder meeting scheduled for December 20th, 2018. Please see below a brief statement from Ilan Danieli, Precipio’s CEO. The purpose of the proposals in the proxy is to create options for the company, to ensure that management has the ability to act quickly in the best interest of the company to protect value to its shareholders.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks To Watch On Wednesday

    CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / Healthcare demand is increasing as an aging population continues to drive new healthcare market growth. The connection between healthcare goods and services is less tied to the economy compared to other sectors, and that could make healthcare stocks the place where investors will look for a hedge as the broader markets see increasing volatility. According to Bureau of Labor Statistics data*, the fastest-growing sectors include healthcare support occupations (23.2% increase from 2016-2026) and healthcare practitioners and technical occupations (15.2%), which entail home health aides, physician assistants and nurse practitioners, among other positions.

  • GlobeNewswire2 months ago

    Webinar to Highlight Technology Underlying Precipio’s ICE COLD-PCR on November 20, 2018

    Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces an upcoming Labroots webinar titled “COLD-PCR technology: current status and application in liquid biopsies for cancer and prenatal diagnosis” on Tuesday, November 20th at 10:00 AM EST (7:00AM PST). The webinar is sponsored by Perkin Elmer and attendees will receive either Professional Acknowledgment for Continuing Education (P.A.C.E.®) or Florida C.E. credit.

  • GlobeNewswire3 months ago

    Precipio and PerkinElmer Collaborate to Provide Solutions for Liquid Biopsy Testing Workflows

    Precipio ICE COLD-PCR™ reagents will be sold with PerkinElmer DNA/RNA extraction and isolation products NEW HAVEN, Conn., Nov. 01, 2018 -- Specialty cancer diagnostics company.

  • GlobeNewswire3 months ago

    Precipio Expands ICE COLD-PCR™ Menu for Breast, Colon and Endometrial Cancers

    NEW HAVEN, Conn., Oct. 23, 2018 (GLOBE NEWSWIRE) --  Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched two new ICEme™ assays using its proprietary ICE-COLD PCR technology. The new ICEme assays cover PIK3CA exons 9 & 20, and achieve a level of sensitivity of 0.1%, enabling their use with liquid biopsies. PIK3CA mutations occur in about 25% to 40% of breast cancer, 36% of endometrial cancer, and 32% of colon cancers.1 Presence of PIK3CA mutations is associated with resistance to various therapies for breast cancer patients, and in fact have indicated resistance to therapies, thus requiring different or more aggressive treatment.

  • GlobeNewswire4 months ago

    Precipio Enters into Exchange Agreement to Restructure Remaining Legacy Accounts Payable for approximately 20% of Original ~$5M

    Specialty cancer diagnostics Company Precipio, Inc. (NASDAQ: PRPO), announces the restructuring of its remaining legacy, pre-merger accounts payable liabilities, pursuant to an exchange which is made in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933. The payments made to note holders are equal to approximately 20% of the original $5.3 million, and are funded through a convertible note with existing investors. Important benefits of this transaction include the postponement of $82,000 in monthly debt service for a period of 12 months, and the ability during that time to convert the notes at a 65% premium to market, effectively reducing by almost half the dilution that would have otherwise resulted from raising capital necessary to satisfy these obligations.

  • ACCESSWIRE5 months ago

    Precipio, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 23, 2018 / Precipio, Inc. (NASDAQ: PRPO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 23, 2018 at 9:00 AM Eastern Time. To ...

  • ACCESSWIRE6 months ago

    Today’s Research Reports on Stocks to Watch: Texas Instruments and Precipio

    NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Texas Instruments Incorporated closed down modestly on Wednesday. The company's CEO Brian Crutcher recently resigned for violating conduct and in his place, former CEO Rich Templeton has taken his position. Shares of Precipio saw big gains after announcing preliminary second quarter results.